EN-US Wed, 22 May 2013 02:25:17 -0400 158865 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FeWnBGDcPoo/hyperion-therapeutics-prices-ipo-at-1000-below-the-range-cm158865 News Headlines IPOs Hyperion Therapeutics, which is focused on the treatment of orphan diseases of the liver relating to the urea cycle, raised $50 million by offering 5 million shares at $10.00, below the range<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/FeWnBGDcPoo" height="1" width="1"/> Thu, 26 Jul 2012 16:49:37 Z 2012-07-26T14:09:22Z Renaissance Capital HPTX http://www.nasdaq.com/article/hyperion-therapeutics-prices-ipo-at-1000-below-the-range-cm158865 157335 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2-Fh3Tfe-Eo/biotech-hyperion-therapeutics-sets-terms-for-50-million-us-ipo-cm157335 News Headlines IPOs Hyperion Therapeutics, a biotech focused on the treatment of urea cycle disorders and hepatic encephalopathy, announced terms for its IPO on Friday. The South San Francisco, CA-based company<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/2-Fh3Tfe-Eo" height="1" width="1"/> Fri, 13 Jul 2012 16:21:30 Z 2012-07-20T13:13:16Z Renaissance Capital HPTX http://www.nasdaq.com/article/biotech-hyperion-therapeutics-sets-terms-for-50-million-us-ipo-cm157335